Clinical Trial Update: Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ST266 ophthalmic drops versus placebo for allergic conjunctivitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• ST266

Snippet

Sponsor: Noveome Biotherapeutics, formerly Stemnion | Conditions: Allergic Conjunctivitis | Phase 2 | Status: COMPLETED | Results posted: 2021-09-16